The European Institute of Innovation and Technology, based in Budapest, Hungary, has appointed its first 18-person governing board. The institute is a new European Union organisation that will promote new technologies in the physical, social and life sciences.
Four days after announcing its first ever research agreement with the University of Cambridge in the UK, GlaxoSmithKline has disclosed a five-year collaboration with the Harvard Stem Cell Institute in the US to discover new therapies based on stem cell science.
GlaxoSmithKline has signed its first ever research agreement with the University of Cambridge in the UK to develop a novel, centrally-acting agent with therapeutic potential for obesity and addictive disorders. Financial terms were not disclosed.
The UK drug development company, Modern Biosciences, has entered into an exclusive agreement with the University of Bradford, also of the UK, to develop a vascular disrupting agent for cancer. Financial terms were not disclosed.
Researchers from Cancer Research UK have identified a new protein target that could be used to produce vaccine therapies for cancer. Their findings are reported in the 22 May 2008 issue of The Journal of Clinical Investigation.
Scientists at the University of Oxford’s Jenner Institute have started a Phase 1 trial for a new candidate vaccine against malaria, which is designed to stimulate an immune response to the malaria parasite by using a genetically modified chimpanzee adenovirus.
A committee of the House of Commons has raised questions about the Labour government’s commitment to a proposed new medical centre for central London following the disclosure that the Treasury has clawed back £92 million from savings accumulated by the Medical Research Council for financing the project.
Ipsen SA of France has signed a memorandum of understanding with The Salk Institute in La Jolla, California, to carry out basic research on proliferative and degenerative diseases.
The UK Medical Research Council (MRC) is planning to spend £12 million over five years to create regional academic centres to investigate new methodologies for clinical trials.
The UK regulator responsible for overseeing embryo research has decided to issue one-year licences to Kings College London and the University of Newcastle Upon Tyne to conduct research using embryos which have been created from some human and some animal material.